'Peptide 1 glp 1' diaporamas de présentation

Peptide 1 glp 1 - PowerPoint PPT Presentation

Diabetes Mellitus

Diabetes Mellitus

Diabetes Mellitus. Lecture 1. Introduction. Diabetes mellitus is a group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.

★ ★ ★ ★ ★

759 views • 75 slides
DIABETES MELLITUS

DIABETES MELLITUS

DIABETES MELLITUS. An Emerging Disaster. Session Objectives. Identify the prevalence of diabetes mellitus (DM) in the Saudi community. Discuss the classification of DM . Discuss the diagnostic criteria for DM. Identify the patho -physiological changes in a diabetic patient.

★ ★ ★ ★ ★

646 views • 57 slides
??? ???? ?????? ??????

??? ???? ?????? ??????

??? ???? ?????? ??????. PHARMACOTHERAPY FOR NASH: CURRENT AND EMERGING. Prof. Dr. Amr Abd Elmoty. Hepatology unit- 18/10/2018.

★ ★ ★ ★ ★

294 views • 29 slides
INCRETINS

INCRETINS

INCRETINS. Glucagon-like Peptide 1 (GLP-1) and Glucose-Dependent Insulinotrophic Polypeptide (GIP) account for ~90% of the incretin effect. In response to equivalent hyperglycemic stimuli, ORAL glucose elicits a greater insulin response than IV glucose. Insulin.

★ ★ ★ ★ ★

365 views • 16 slides
Therapy of Type 2 Diabetes Mellitus: UPDATE

Therapy of Type 2 Diabetes Mellitus: UPDATE

Therapy of Type 2 Diabetes Mellitus: UPDATE. Glycemic Goals in the Care of Patients with Type 2 Diabetes- 2013 ADA and AACE Guidelines: Room For Improvement (Be HAPPY/ Avoid Burnout, While Caring for Patients with DM). Stan Schwartz MD, FACP, FACE Affiliate, Main Line Health System

★ ★ ★ ★ ★

703 views • 14 slides
Therapy of Type 2 Diabetes Mellitus: UPDATE

Therapy of Type 2 Diabetes Mellitus: UPDATE

Therapy of Type 2 Diabetes Mellitus: UPDATE. Glycemic Goals in the Care of Patients with Type 2 Diabetes- 2013 ADA and AACE Guidelines: Room For Improvement (Be HAPPY/ Avoid Burnout, While Caring for Patients with DM). Stan Schwartz MD, FACP, FACE Affiliate, Main Line Health System

★ ★ ★ ★ ★

172 views • 13 slides
Changes in Gastrointestinal Hormones after the Roux-en-Y Gastric Bypass Procedure: A Review

Changes in Gastrointestinal Hormones after the Roux-en-Y Gastric Bypass Procedure: A Review

Changes in Gastrointestinal Hormones after the Roux-en-Y Gastric Bypass Procedure: A Review. Lauren M. Beckman, MS, RD: University of Minnesota (UM) Tiffany R. Beckman, MD, MPH: UM Carrie P. Earthman, PhD, RD, LD: UM. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION.

★ ★ ★ ★ ★

453 views • 12 slides
GLP-1 Agonists and Cardiovascular Health

GLP-1 Agonists and Cardiovascular Health

GLP-1 Agonists and Cardiovascular Health. Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM. Part 2 of 2. Change in Weight by Quartile at 82 Weeks. Change in A1C as a Function of Change in Weight at 82 Weeks.

★ ★ ★ ★ ★

163 views • 12 slides
Metformin and its gastrointestinal problems: A review

Metformin and its gastrointestinal problems: A review

Metformin is a biguanide class of drugs and has been recommended as first-line therapy for type 2 diabetes. It has a good safety profile, efficacy, comparatively reduced cost, and potential cardiovascular benefits. Metformin is an insulin-sensitizing agent, its bioavailability is 50%-60%. Generally, A1C levels are lowered by 1.5% points by metformin monotherapy. Treatment with metformin decreases fasting plasma glucose concentrations by 25% to 30% and decreases the production of glucose.

★ ★ ★ ★ ★

53 views • 5 slides

View Peptide 1 glp 1 PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Peptide 1 glp 1 PowerPoint presentations. You can view or download Peptide 1 glp 1 presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.